ATP Clinical Research, Inc.
Welcome,         Profile    Billing    Logout  
 9 Trials 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Alva, Gustavo
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting
2/3
225
Canada, US
Piromelatine 20 mg, Neu-P11, Placebo
Neurim Pharmaceuticals Ltd., Syneos Health
Alzheimer's Disease
06/25
06/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed
2
15
US
ANC-501
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Major Depressive Disorder
08/23
10/23
REGEN-BRAIN©, NCT04838301: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Recruiting
2
200
US
Allopregnanolone, Allo, Placebo
University of Arizona, National Institute on Aging (NIA), Syneos Health, University of Southern California, ADM Diagnostics
Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
04/25
12/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Shih, Bobby
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
INVOKE-2, NCT04592874 / 2019-001476-11: A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Completed
2
381
Europe, Canada, US, RoW
AL002, Placebo
Alector Inc., AbbVie
Alzheimer Disease
08/24
09/24
REGEN-BRAIN©, NCT04838301: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Recruiting
2
200
US
Allopregnanolone, Allo, Placebo
University of Arizona, National Institute on Aging (NIA), Syneos Health, University of Southern California, ADM Diagnostics
Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
04/25
12/26
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
Hope, NCT05637801: A Pivotal Study of Sensory Stimulation in Alzheimer's Disease ( Study, CA-0011)

Recruiting
N/A
600
US
Sensory Stimulation System (GS120) - Active, Sensory Stimulation System (GS120) - Sham
Cognito Therapeutics, Inc.
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
11/25
12/25
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Alva, Alejandro
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
Flores, Vanessa
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
Bisesi, Lorrie
NCT04958031: A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Completed
2
41
Canada, US
CVL-871 1.0 mg, CVL-871 3.0 mg, Placebo
AbbVie
Apathy in Dementia
02/25
02/25
Hope, NCT05637801: A Pivotal Study of Sensory Stimulation in Alzheimer's Disease ( Study, CA-0011)

Recruiting
N/A
600
US
Sensory Stimulation System (GS120) - Active, Sensory Stimulation System (GS120) - Sham
Cognito Therapeutics, Inc.
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
11/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Alva, Gustavo
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Recruiting
3
255
US
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
02/25
02/26
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting
2/3
225
Canada, US
Piromelatine 20 mg, Neu-P11, Placebo
Neurim Pharmaceuticals Ltd., Syneos Health
Alzheimer's Disease
06/25
06/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed
2
15
US
ANC-501
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Major Depressive Disorder
08/23
10/23
REGEN-BRAIN©, NCT04838301: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Recruiting
2
200
US
Allopregnanolone, Allo, Placebo
University of Arizona, National Institute on Aging (NIA), Syneos Health, University of Southern California, ADM Diagnostics
Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
04/25
12/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Shih, Bobby
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
INVOKE-2, NCT04592874 / 2019-001476-11: A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Completed
2
381
Europe, Canada, US, RoW
AL002, Placebo
Alector Inc., AbbVie
Alzheimer Disease
08/24
09/24
REGEN-BRAIN©, NCT04838301: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Recruiting
2
200
US
Allopregnanolone, Allo, Placebo
University of Arizona, National Institute on Aging (NIA), Syneos Health, University of Southern California, ADM Diagnostics
Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
04/25
12/26
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
Hope, NCT05637801: A Pivotal Study of Sensory Stimulation in Alzheimer's Disease ( Study, CA-0011)

Recruiting
N/A
600
US
Sensory Stimulation System (GS120) - Active, Sensory Stimulation System (GS120) - Sham
Cognito Therapeutics, Inc.
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
11/25
12/25
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Alva, Alejandro
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
Flores, Vanessa
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
Bisesi, Lorrie
NCT04958031: A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Completed
2
41
Canada, US
CVL-871 1.0 mg, CVL-871 3.0 mg, Placebo
AbbVie
Apathy in Dementia
02/25
02/25
Hope, NCT05637801: A Pivotal Study of Sensory Stimulation in Alzheimer's Disease ( Study, CA-0011)

Recruiting
N/A
600
US
Sensory Stimulation System (GS120) - Active, Sensory Stimulation System (GS120) - Sham
Cognito Therapeutics, Inc.
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
11/25
12/25

Download Options